UBS lowered the firm’s price target on Arrowhead to $75 from $78 and keeps a Buy rating on the shares. Arrowhead reported Q1 results and announced restructuring and operating cash burn reductions, the analyst tells investors in a research note. The firm sees long-term value in Arrowhead’s RNAi platform at current levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARWR:
- ARWR Upcoming Earnings Report: What to Expect?
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential
- Arrowhead price target raised to $62 from $59 at Piper Sandler
- Arrowhead 15.8M share Secondary priced at $28.50
